Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 16;4(6):e001921.
doi: 10.1136/bmjgh-2019-001921. eCollection 2019.

Effects of PACK guide training on the management of asthma and chronic obstructive pulmonary disease by primary care clinicians: a pragmatic cluster randomised controlled trial in Florianópolis, Brazil

Max Oscar Bachmann  1 , Eric D Bateman  2 , Rafael Stelmach  3 , Alvaro A Cruz  4 , Matheus Pacheco de Andrade  5 , Ronaldo Zonta  5 , Jorge Zepeda  6 , Sonia Natal  7 , Ruth Vania Cornick  2 , Camilla Wattrus  2 , Lauren Anderson  2 , Daniella Georgeu-Pepper  2 , Carl Lombard  8 , Lara R Fairall  2
Affiliations

Effects of PACK guide training on the management of asthma and chronic obstructive pulmonary disease by primary care clinicians: a pragmatic cluster randomised controlled trial in Florianópolis, Brazil

Max Oscar Bachmann et al. BMJ Glob Health. .

Abstract

Introduction: The Practical Approach to Care Kit (PACK) guide was localised for Brazil, where primary care doctors and nurses were trained to use it.

Methods: Twenty-four municipal clinics in Florianópolis were randomly allocated to receive outreach training and the guide, and 24 were allocated to receive only the guide. 6666 adult patients with asthma or chronic obstructive pulmonary disease (COPD) were enrolled, and trial outcomes were measured over 12 months, using electronic medical records. The primary outcomes were composite scores of treatment changes and spirometry, and new asthma and COPD diagnosis rates.

Results: Asthma scores in 2437 intervention group participants were higher (74.8%, 20.4% and 4.8% with scores of 0, 1 and 2, respectively) than in 2633 control group participants (80.0%, 16.8% and 3.2%) (OR for higher score 1.32, 95% CI 1.08 to 1.61, p=0.006). Adjusted for asthma scores recorded in each clinic before training started, the OR was 1.24 (95% CI 1.03 to 1.50, p=0.022). COPD scores in 1371 intervention group participants (77.7%, 17.9% and 4.3% with scores of 0, 1 and 2) did not differ from those in 1181 control group participants (80.5%, 15.8% and 3.7%) (OR 1.21, 95% CI 0.94 to 1.55, p=0.142). Rates of new asthma and COPD diagnoses, and hospital admission, and indicators of investigation, diagnosis and treatment of comorbid cardiovascular disease, diabetes and depression, and tobacco cessation did not differ between trial arms.

Conclusion: PACK training increased guideline-based treatment and spirometry for asthma but did not affect COPD or comorbid conditions, or diagnosis rates.

Trial registration: NCT02786030 (https://clinicaltrials.gov/).

Keywords: educational outreach; implementation research; primary care; respiratory disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: We have read and understood BMJ policy on declaration of interests and declare that CW, LRF, DG-P, LA, RVC and EDB are employees of the KTU. RZ and MPdA are employees of the City Health Department, Florianópolis, Brazil. JZ is an ex-employee of the City Health Department, Florianópolis, Brazil and a current holder of full-time PhD studentship from the Brazilian research agency CNPq. AAC reports grants, personal fees and non-financial support from GSK, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from MEDA, personal fees and non-financial support from Novartis, personal fees and non-financial support from EUROFARMA, personal fees and non-financial support from CHIESI, personal fees and non-financial support from Boston Scientific, outside the submitted work. EDB reports grants to institution for clinical trials from Novartis, Boehringer Ingelheim, Merck, Takeda, GlaxoSmithKline, Hoffmann La Roche, Actelion, Chiesi, Sanofi-Aventis, Cephalon, TEVA and AstraZeneca and personal fees from ICON, Novartis, Cipla, Vectura, Cipla, Menarini, ALK, ICON, Sanofi Regeneron, Boehringer Ingelheim and AstraZeneca, outside the submitted work, and is a Member of Global Initiative for Asthma Board and Science Committee. RS reports grants for clinical trials, personal, institution fees and non-financial support from AstraZeneca, and personal fees and non-financial support from Novartis, Boehringer Ingelheim, CHIESI and EUROFARMA. Since August 2015, the KTU and BMJ have been engaged in a non-profit strategic partnership to provide continuous evidence updates for PACK, expand PACK-related supported services to countries and organisations as requested, and where appropriate license PACK content. The KTU and BMJ co-fund core positions, including a PACK Global Development Director, and receive no profits from the partnership. PACK receives no funding from the pharmaceutical industry. This paper forms part of a Collection on PACK sponsored by the BMJ to profile the contribution of PACK across several countries towards the realisation of comprehensive primary health care as envisaged in the Declarations of Alma Ata and Astana.

Figures

Figure 1
Figure 1
Timing of interventions, data collection and follow-up periods.
Figure 2
Figure 2
CONSORT diagram of recruitment and follow-up in intervention and control clinics. COPD, chronic obstructive pulmonary disease.
See this image and copyright information in PMC

References

    1. GBD 2016 Brazil Collaborators Burden of disease in Brazil, 1990–2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:760–75. 10.1016/S0140-6736(18)31221-2 - DOI - PMC - PubMed
    1. Casas A, Montes de Oca M, Menezes AM, et al. . Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Int J Chron Obstruct Pulmon Dis 2018;13:1545–56. 10.2147/COPD.S154097 - DOI - PMC - PubMed
    1. To T, Stanojevic S, Moores G, et al. . Global asthma prevalence in adults: findings from the cross-sectional World Health Survey. BMC Public Health 2012;12 10.1186/1471-2458-12-204 - DOI - PMC - PubMed
    1. Rzewuska M, de Azevedo-Marques JM, Coxon D, et al. . Epidemiology of multimorbidity within the Brazilian adult general population: evidence from the 2013 National Health Survey (PNS 2013). PLoS One 2017;12:e0171813 10.1371/journal.pone.0171813 - DOI - PMC - PubMed
    1. Massuda A, Hone T, Leles FAG, et al. . The Brazilian health system at crossroads: progress, crisis and resilience. BMJ Glob Health 2018;3:e000829 10.1136/bmjgh-2018-000829 - DOI - PMC - PubMed

Associated data

LinkOut - more resources